MA43528A - Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih - Google Patents
Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vihInfo
- Publication number
- MA43528A MA43528A MA043528A MA43528A MA43528A MA 43528 A MA43528 A MA 43528A MA 043528 A MA043528 A MA 043528A MA 43528 A MA43528 A MA 43528A MA 43528 A MA43528 A MA 43528A
- Authority
- MA
- Morocco
- Prior art keywords
- hiv integrase
- integrase inhibitors
- tricyclic compounds
- compounds condensed
- heterocyclic tricyclic
- Prior art date
Links
- 229940099797 HIV integrase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003084 hiv integrase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/100106 WO2017113288A1 (en) | 2015-12-31 | 2015-12-31 | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43528A true MA43528A (fr) | 2018-11-07 |
Family
ID=57799839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043528A MA43528A (fr) | 2015-12-31 | 2016-12-22 | Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20170190701A1 (enExample) |
| EP (1) | EP3397639B1 (enExample) |
| JP (1) | JP2019500387A (enExample) |
| KR (1) | KR20180095833A (enExample) |
| CN (1) | CN108473494A (enExample) |
| AR (1) | AR107170A1 (enExample) |
| AU (1) | AU2016381072B2 (enExample) |
| BR (1) | BR112018013251A2 (enExample) |
| CA (1) | CA3008018A1 (enExample) |
| JO (1) | JO3811B1 (enExample) |
| MA (1) | MA43528A (enExample) |
| MX (1) | MX2018008095A (enExample) |
| RU (1) | RU2740187C2 (enExample) |
| TW (1) | TW201726683A (enExample) |
| WO (2) | WO2017113288A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081647B2 (en) * | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
| KR20210005139A (ko) * | 2018-04-27 | 2021-01-13 | 머크 샤프 앤드 돔 코포레이션 | Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물 |
| IL313474A (en) | 2018-05-31 | 2024-08-01 | Shionogi & Co | Polycyclic carbamoylpyridone derivative |
| SG11202011386QA (en) | 2018-05-31 | 2020-12-30 | Shionogi & Co | Polycyclic pyridone derivative |
| WO2019236396A1 (en) * | 2018-06-05 | 2019-12-12 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| ES2970251T3 (es) * | 2018-10-22 | 2024-05-27 | Univ Nebraska | Profármacos antivirales y nanoformulaciones de los mismos |
| HUE059677T2 (hu) | 2019-03-22 | 2022-12-28 | Gilead Sciences Inc | Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| CR20220418A (es) | 2020-02-24 | 2022-10-10 | Gilead Sciences Inc | Compuestos tetracíclicos para el tratamiento de infecciones por vih |
| JP7691494B2 (ja) | 2020-09-30 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | 架橋三環式カルバモイルピリドン化合物及びその使用 |
| LT4196479T (lt) | 2021-01-19 | 2023-12-11 | Gilead Sciences, Inc. | Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai |
| CA3208396A1 (en) * | 2021-02-16 | 2022-08-25 | Timothy John Hartingh | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE15187654T1 (de) | 2001-08-10 | 2016-12-01 | Shionogi & Co., Ltd | Antivirales Mittel |
| AU2002334205B2 (en) | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
| US7169780B2 (en) | 2001-10-26 | 2007-01-30 | Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| US7279487B2 (en) | 2002-01-17 | 2007-10-09 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors |
| AU2003292436B2 (en) | 2002-12-27 | 2009-07-30 | Msd Italia S.R.L. | Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors |
| US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (en) * | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| EP1866313A1 (en) | 2005-03-31 | 2007-12-19 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
| US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| CN101346376A (zh) * | 2005-10-27 | 2009-01-14 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的多环性氨基甲酰基吡啶酮衍生物 |
| US7897592B2 (en) | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| MY158520A (en) * | 2008-10-07 | 2016-10-14 | Actelion Pharmaceuticals Ltd | Tricyclic oxazolidinone antibiotic compounds |
| CA2777664C (en) | 2009-10-13 | 2014-06-10 | Johannes Wilhelmus J. Thuring | Macrocyclic integrase inhibitors |
| CN102958935B (zh) | 2010-04-02 | 2015-12-09 | 爱尔兰詹森科学公司 | 大环整合酶抑制剂 |
| EP2986291B1 (en) * | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| AU2014267951A1 (en) * | 2013-05-17 | 2015-11-19 | Merck Sharp & Dohme Corp. | Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors |
-
2015
- 2015-12-31 WO PCT/CN2015/100106 patent/WO2017113288A1/en not_active Ceased
-
2016
- 2016-12-22 TW TW105142826A patent/TW201726683A/zh unknown
- 2016-12-22 JP JP2018534101A patent/JP2019500387A/ja active Pending
- 2016-12-22 CN CN201680073126.9A patent/CN108473494A/zh active Pending
- 2016-12-22 AR ARP160103990A patent/AR107170A1/es unknown
- 2016-12-22 EP EP16826561.9A patent/EP3397639B1/en active Active
- 2016-12-22 BR BR112018013251A patent/BR112018013251A2/pt not_active Application Discontinuation
- 2016-12-22 WO PCT/US2016/068173 patent/WO2017116928A1/en not_active Ceased
- 2016-12-22 RU RU2018127728A patent/RU2740187C2/ru active
- 2016-12-22 JO JOP/2016/0271A patent/JO3811B1/ar active
- 2016-12-22 CA CA3008018A patent/CA3008018A1/en not_active Abandoned
- 2016-12-22 MA MA043528A patent/MA43528A/fr unknown
- 2016-12-22 MX MX2018008095A patent/MX2018008095A/es unknown
- 2016-12-22 KR KR1020187018217A patent/KR20180095833A/ko not_active Withdrawn
- 2016-12-22 AU AU2016381072A patent/AU2016381072B2/en not_active Ceased
- 2016-12-22 US US15/387,732 patent/US20170190701A1/en not_active Abandoned
-
2017
- 2017-12-13 US US15/840,017 patent/US20180099967A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,857 patent/US20190322666A1/en not_active Abandoned
-
2020
- 2020-10-27 US US17/081,094 patent/US20210040096A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2740187C2 (ru) | 2021-01-12 |
| AU2016381072B2 (en) | 2020-11-26 |
| JP2019500387A (ja) | 2019-01-10 |
| RU2018127728A (ru) | 2020-02-03 |
| US20190322666A1 (en) | 2019-10-24 |
| JO3811B1 (ar) | 2021-01-31 |
| MX2018008095A (es) | 2018-08-23 |
| EP3397639B1 (en) | 2022-02-23 |
| EP3397639A1 (en) | 2018-11-07 |
| AR107170A1 (es) | 2018-03-28 |
| US20180099967A1 (en) | 2018-04-12 |
| CA3008018A1 (en) | 2017-07-06 |
| WO2017113288A1 (en) | 2017-07-06 |
| RU2018127728A3 (enExample) | 2020-02-14 |
| KR20180095833A (ko) | 2018-08-28 |
| BR112018013251A2 (pt) | 2018-12-04 |
| WO2017116928A1 (en) | 2017-07-06 |
| AU2016381072A1 (en) | 2018-05-31 |
| US20170190701A1 (en) | 2017-07-06 |
| US20210040096A1 (en) | 2021-02-11 |
| TW201726683A (zh) | 2017-08-01 |
| CN108473494A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43528A (fr) | Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih | |
| DK3735299T3 (da) | Kondenserede ringforbindelser | |
| EP3414224A4 (en) | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| PT3523390T (pt) | Utilização de composições à base de tetrafluoropropeno | |
| EP3464275A4 (en) | EGFR INHIBITOR COMPOUNDS | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| EP3752144A4 (en) | TETRACYCLIC HETEROCYCLENE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | |
| EP2997033A4 (en) | CONDENSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | |
| EP3353278A4 (en) | SPECIMEN PREPARATION FOR HEAVY SPECIMENS | |
| ME03334B (me) | Heteroarilna jedinjenja za inhibiciju kinaza | |
| EP3337787A4 (en) | PYRAZOLO-CONDENSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | |
| MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
| EP3548031A4 (en) | TETRACYCLIC HETEROCYCLENE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | |
| EP3377065A4 (en) | SPIROCYCLIC PYRIDOTRIAZINE DERIVATIVES FOR USE AS HIV INTEGRASE INHIBITORS | |
| EP3377066A4 (en) | AMIDOSUBSTITUTED PYRIDOTRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | |
| EP3784241A4 (en) | TETRACYCLIC HETEROCYCLENIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | |
| IL266908A (en) | Heterocyclic tetracyclic compounds for use as hiv integrase inhibitors | |
| EP2871957A4 (en) | MACROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | |
| EP3389380A4 (en) | SPIROCYCLIC CHINOLIZIN DERIVATIVES FOR USE AS HIV INTEGRASE INHIBITORS | |
| DK3386991T3 (da) | Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase | |
| EP3630775A4 (en) | 6-5 MERGED CYCLES USED AS C5A INHIBITORS |